Bio-Techne Corp. Stock
Bio-Techne Corp. Stock
A loss of -1.900% shows a downward development for Bio-Techne Corp..
Bio-Techne Corp. is currently one of the favorites of our community with 18 Buy predictions and no Sell predictions.
As a result the target price of 60 € shows a slightly positive potential of 16.5% compared to the current price of 51.5 € for Bio-Techne Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Bio-Techne Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Bio-Techne Corp. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Bio-Techne Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bio-Techne Corp. | -1.900% | -2.830% | -2.830% | -29.932% | -25.899% | -34.810% | - |
| Icu Medical Inc. | 0.000% | 3.306% | 1.626% | -20.886% | -14.966% | -14.966% | -22.360% |
| Bio-Rad Labs Inc. A | 1.740% | -1.966% | -4.673% | -17.189% | -14.263% | -31.823% | -41.201% |
| Neogen Corp. | -2.480% | 13.592% | 4.464% | -51.250% | -51.250% | - | - |
Comments
Bio-Techne (NASDAQ:TECH) was given a new $72.00 price target on by analysts at Deutsche Bank Aktiengesellschaft. They now have a "buy" rating on the stock.
Show more
Ratings data for TECH provided by MarketBeat
Bio-Techne (NASDAQ:TECH) had its price target raised by analysts at Argus from $65.00 to $68.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TECH provided by MarketBeat
Bio-Techne (NASDAQ:TECH) had its price target raised by analysts at UBS Group AG from $65.00 to $70.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TECH provided by MarketBeat